The Library
To push or to pull? In a post-COVID world, supporting and incentivizing antimicrobial drug development must become a governmental priority
Tools
Tools
Tools
Cama, J., Leszczynski, R., Tang, P. K., Khalid, A., Lok, V., Dowson, Christopher G. and Ebata, A. (2021) To push or to pull? In a post-COVID world, supporting and incentivizing antimicrobial drug development must become a governmental priority. ACS Infectious Diseases . doi:10.1021/acsinfecdis.0c00681 (In Press)
|
PDF
WRAP-To-push-to-pull-post-COVID-world-supporting-antimicrobial-drug-2021.pdf - Accepted Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1282Kb) | Preview |
Official URL: http://dx.doi.org/10.1021/acsinfecdis.0c00681
Abstract
The COVID-19 pandemic has refocused attention worldwide on the dangers of infectious diseases, in terms of both global health and the effects on the world economy. Even in high income countries, health systems have been found wanting in dealing with the new infectious agent. However, the even greater long-term danger of antimicrobial resistance in pathogenic bacteria and fungi is still under-appreciated, especially among the general public. Although antimicrobial drug development faces significant scientific challenges, the gravest challenge at the moment appears to be economic, where the lack of a viable market has led to a collapse in drug development pipelines. There is therefore a critical need for governments across the world to further incentivize the development of antimicrobials. Most incentive strategies over the past decade have focused on so-called “push” incentives that bridge the costs of antimicrobial research and development, but these have been insufficient for reviving the pipeline. In this Perspective, we analyze the current incentive strategies in place for antimicrobial drug development, and focus on “pull” incentives, which instead aim to improve revenue generation and thereby resolve the antimicrobial market failure challenge. We further analyze these incentives in a broader “One Health” context and stress the importance of developing and enforcing strict protocols to ensure appropriate manufacturing practices and responsible use. Our analysis reiterates the importance of international cooperation, coordination across antimicrobial research, and sustained funding in tackling this significant global challenge. A failure to invest wisely and continuously to incentivize antimicrobial pipelines will have catastrophic consequences for global health and wellbeing in the years to come.
| Item Type: | Journal Article | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QR Microbiology R Medicine > RB Pathology R Medicine > RM Therapeutics. Pharmacology |
||||||||||||
| Divisions: | Faculty of Science > Life Sciences (2010- ) | ||||||||||||
| Library of Congress Subject Headings (LCSH): | Anti-infective agents, Anti-infective agents -- Development, Drug resistance in microorganisms , Drug resistance in microorganisms -- Prevention -- Government policy, Microorganisms -- Effect of drugs on | ||||||||||||
| Journal or Publication Title: | ACS Infectious Diseases | ||||||||||||
| Publisher: | American Chemical Society (ACS) | ||||||||||||
| ISSN: | 2373-8227 | ||||||||||||
| Official Date: | 19 February 2021 | ||||||||||||
| Dates: |
|
||||||||||||
| Date of first compliant deposit: | 22 February 2021 | ||||||||||||
| DOI: | 10.1021/acsinfecdis.0c00681 | ||||||||||||
| Status: | Peer Reviewed | ||||||||||||
| Publication Status: | In Press | ||||||||||||
| Access rights to Published version: | Open Access | ||||||||||||
| Copyright Holders: | © 2021 American Chemical Society | ||||||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
